Thermo Fisher Scientific (NYSE:TMO) Stock Price Target Raised at Robert W. Baird

Key Points

• Robert W. Baird raised Thermo Fisher Scientific’s price target to $756 from $723 and maintained an “outperform” rating, implying about 8.9% upside. Analysts overall rate the stock “Moderate Buy,” with a consensus target of $664.33.
• Thermo Fisher exceeded third-quarter expectations, reporting EPS of $6.68 versus the $6.40 consensus and revenue of $12.14 billion versus estimates of $11.95 billion; revenue increased 9.1% year over year.
• Management raised its 2026 organic revenue-growth outlook to 4%, supported by improving demand and margins. However, insiders sold about $44.1 million of stock over the past three months, while elevated put-option activity suggests some near-term investor caution.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) had its price target lifted by equities researchers at Robert W. Baird from $723.00 to $756.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an "outperform" rating on the medical research company's stock. Robert W. Baird's target price points to a potential upside of 8.94% from the stock's current price.

Several other equities research analysts also recently issued reports on TMO. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, August 5th. Royal Bank Of Canada set a $740.00 target price on Thermo Fisher Scientific in a research note on Thursday, October 15th. Jefferies Financial Group reissued a "buy" rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $720.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $664.33.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $693.98 on Thursday. The company has a market cap of $256.60 billion, a P/E ratio of 37.33, a P/E/G ratio of 2.87 and a beta of 0.87. The firm's fifty day moving average price is $642.42 and its two-hundred day moving average price is $552.67. Thermo Fisher Scientific has a one year low of $435.27 and a one year high of $705.79. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.40 by $0.28. The company had revenue of $12.14 billion during the quarter, compared to analysts' expectations of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific's quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company posted $5.79 EPS. Equities analysts expect that Thermo Fisher Scientific will post 25.13 earnings per share for the current year.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. This represents a 1.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMO. Strengthening Families & Communities LLC increased its position in shares of Thermo Fisher Scientific by 0.4% in the third quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company's stock worth $3,187,000 after purchasing an additional 21 shares during the period. Bell Bank lifted its position in Thermo Fisher Scientific by 10.8% during the third quarter. Bell Bank now owns 624 shares of the medical research company's stock worth $421,000 after purchasing an additional 61 shares during the period. 55 North Private Wealth LLC grew its stake in Thermo Fisher Scientific by 40.9% during the third quarter. 55 North Private Wealth LLC now owns 906 shares of the medical research company's stock worth $612,000 after buying an additional 263 shares in the last quarter. Jeppson Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the third quarter worth about $213,000. Finally, James Hambro & Partners LLP increased its holdings in Thermo Fisher Scientific by 0.8% in the 3rd quarter. James Hambro & Partners LLP now owns 231,390 shares of the medical research company's stock valued at $156,260,000 after buying an additional 1,919 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 results exceeded expectations. Thermo Fisher reported adjusted EPS of $6.68, above the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, surpassing estimates of approximately $11.95 billion. Adjusted EPS increased 15%, supported by stronger operating performance. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Organic growth and margins improved. Organic revenue growth reached 6%, with particularly solid demand in clinical research, bioproduction and electron microscopy. Operating margin expanded to 24.5%, aided by portfolio actions, acquisitions and productivity improvements. Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore
• Positive Sentiment: Management raised its outlook. Thermo Fisher lifted its full-year 2026 organic revenue-growth forecast to 4% and highlighted continued customer activity and confidence in sustained, multi-year expansion. Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Early market reaction was volatile. Shares initially declined in premarket trading despite the earnings beat, suggesting that elevated expectations or profit-taking temporarily offset the favorable results before the stock reversed higher. TMO Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Unusual put-option activity signals near-term caution. Investors purchased 4,906 put options, about 52% above average daily volume, indicating some traders are hedging against volatility or a pullback following the earnings release.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.